title: Clinical study on treatment of mammary cancer by shenqi fuzheng injection in cooperation with chemotherapy.
abstract: OBJECTIVE
  To study the effect of Shenqi Fuzheng Injection (SFI) on cellular immune in patients with mammary cancer (MC) after chemotherapy.
  
  
  METHODS
  One hundred and ten patients with MC were randomly assigned to two groups. The 58 patients in the tested group were treated with SFI in cooperation with chemotherapy of CAF protocol (Cyclophosphamide, Doxorubicin and Fluorouracil), while the 52 patients in the control group were treated with chemotherapy of the same protocol alone. Changes of the patients' quality of life (QOF), adverse reaction that occurred, peripheral lymphocyte count and killing activity of single karyocyte before and after treatment between the two groups were compared.
  
  
  RESULTS
  Patients' QOF elevating rate after treatment in the tested group and the control group was 34.5% and 13.5% respectively; The lowering of peripheral blood cell count of WBC, platelet and lymphocyte as well as that of the killing activity of single peripheral karyocyte on various kinds of MC cells were all milder and recovery sooner than those in the control group.
  
  
  CONCLUSIONS
  SFI in combination with chemotherapy in treating MC could reduce the occurrence of adverse reaction to chemotherapy, improve clinical symptoms, elevate QOF and enhance immunity in patients with MC.
authors.affiliation: Department of Biomedical Engineering, Affiliated Hospital of Guangzhou Medical College, Guangzhou 510095. mammothbo@163.com
authors.forename: Yang
authors.initials: Y
authors.lastname: Bo
authors.forename: Hong-sheng
authors.initials: HS
authors.lastname: Li
authors.forename: Yan-chao
authors.initials: YC
authors.lastname: Qi
authors.forename: Min-ying
authors.initials: MY
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*; D016923:Cell Death; D000529:Complementary Therapies; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007267:Injections; D016131:Lymphocyte Subsets / Q000473:pathology; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D011788:Quality of Life
chemical_list: D004365:Drugs, Chinese Herbal; C521737:shenqi fuzheng; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil